Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation

European Heart Journal

Volumn 33, Issue 15, 2012, Pages 1886-1892

  Raunso, Jakob ^a,d   Selmer, Christian ^a   Olesen, Jonas Bjerring ^a   Charlot, Mette Gitz ^a   Olsen, Anne Marie S ^a   Bretler, Ditte Marie ^a   Nielsen, Jorn Dalsgaard ^b   Dominguez, Helena ^a   Gadsboll, Niels ^c   Kober, Lars ^b   Gislason, Gunnar H ^a   Torp Pedersen, Christian ^a   Hansen, Morten Lock ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c KØGE HOSPITAL   (Denmark)

^d Mental Health Services CPH   (Denmark)

Author keywords

Atrial fibrillation; Rebound; Thrombo embolism; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DENMARK; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CAUSE OF DEATH; DENMARK; FEMALE; HOSPITALIZATION; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; WARFARIN; WITHHOLDING TREATMENT;

EID: 84864575358     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr454     Document Type: Article

References (35)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL,Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006;48:854-906.
2. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson SB, Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann LS, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57: 223-242.
3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
4. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359-364.
5. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
6. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131: 927-934.
7. Hansen ML, Gadsboll N, Gislason GH, Abildstrom SZ, Schramm TK, Folke F, Friberg J, Sorensen R, Rasmussen S, Poulsen HE, Kober L, Madsen M, Torp-Pedersen C. Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers. Europace 2008;10: 395-402.
8. Gaist D, Andersen M, Aarup AL, Hallas J, Gram LF. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997;43:429-433.
9. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445-448.
10. Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, Rasmussen S, Kober L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-1158.
11. Andersson C, Norgaard ML, Hansen PR, Fosbol EL, Schmiegelow M, Weeke P, Olesen JB, Raunso J, Jorgensen CH, Vaag A, Kober L, Torp-Pedersen C, Gislason GH. Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. Eur J Heart Fail 2010;12:1333-1338.
12. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
13. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunso J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-749.
14. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870.
15. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010;4:51-60.
16. Sherman DG, Kim SG, Boop BS, Corley SD, Dimarco JP, Hart RG, Haywood LJ, Hoyte K, Kaufman ES, Kim MH, Nasco E, Waldo AL. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. Arch Intern Med 2005;165:1185-1191.
17. Vinik R,Wanner N, Pendleton RC. Periprocedural antithrombotic management: a review of the literature and practical approach for the hospitalist physician. J Hosp Med 2009;4:551-559.
18. Jamula E, Lloyd NS, Schwalm JD, Airaksinen KE, Douketis JD. Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis. Chest 2010;138:840-847.
19. Ghanbari H, Feldman D, Schmidt M, Ottino J, Machado C, Akoum N, Wall TS, Daccarett M. Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios. Pacing Clin Electrophysiol 2010; 33:400-406.
20. Jaffer AK, Brotman DJ, Bash LD, Mahmood SK, Lott B, White RH. Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med 2010;123:141-150.
21. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA. Dual antiplatelet therapy and heparin bridging significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010;55: 2376-2382.
22. Armstrong MJ, Schneck MJ, Biller J. Discontinuation of perioperative antiplatelet and anticoagulant therapy in stroke patients. Neurol Clin 2006;24:607-630.
23. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008;168:63-69.
24. Poller L, Thomson J. Evidence for rebound hypercoagulability after stopping anticoagulants. Lancet 1964;2:62-64.
25. Van Cleve R. The rebound phenomenon-fact or fancy? Experience with discontinuation of long-term anticoagulation therapy after myocardial infarction. Circulation 1965;32:878-880.
26. Michaels L, Beamish RE. Relapses of thromboembolic disease after discontinued anticoagulant therapy. A comparison of the incidence after abrupt and after gradual termination of treatment. Am J Cardiol 1967;20:670-673.
27. Harenberg J, Haas R, Zimmermann R. Plasma hypercoagulability after termination of oral anticoagulants. Thromb Res 1983;29:627-633.
28. Grip L, Blomback M, Schulman S. Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients. Eur Heart J 1991;12:1225-1233.
29. Palareti G, Legnani C, Guazzaloca G, Frascaro M, Grauso F, De Rosa F, Fortunato G, Coccheri S. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants-a prospective study. Thromb Haemost 1994;72: 222-226.
30. Palareti G, Legnani C, Frascaro M, Guazzaloca G, Coccheri S. Factor VIII: C levels during oral anticoagulation and after its withdrawal. Thromb Haemost 1995;74: 1609-1610.
31. Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996;92:479-485.
32. Palareti G, Legnani C. Warfarin withdrawal. Pharmacokinetic- pharmacodynamic considerations. Clin Pharmacokinet 1996;30:300-313.
33. Nielsen HW, Tuchsen F, Jensen MV. Validity of the diagnosis 'essential hypertension' in the National Patient Registry. Ugeskr Laeger 1996;158:163-167.
34. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 2007;28:150-154.
35. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005;112:1736-1742.